Tag: Diabetes
Quipt makes play for diabetes
May 17, 2024Theresa Flaherty, Managing Editor
CINCINNATI – Quipt Home Medical has dipped its toe into the diabetes market, which company execs say represents a “promising avenue” for growth.
The company started testing the market in fiscal 2023, offering CGMs and supplies in certain markets, CEO Greg Crawford said on a call to discuss second fiscal quarter 2024 earnings.
“The early signs have looked pretty good for us, so now we're in the process of expanding that around the rest of the company,”...
Insulet reports earnings increase, gains market share
May 15, 2024HME News Staff
ACTON, Mass. – Insulet reported revenue of $441.7 million for the first quarter 2024, an increase of 23.3% compared to the prior year. Total Omnipod revenue was $433.0 million, an increase of 21.1%, with U.S. Omnipod revenue $317.7 million. “We are pleased with our strong first quarter results, which underscore the strength of our advanced technology platform and deep competitive advantages,” said Jim Hollingshead, president and CEO. “During the quarter, we achieved strong...
AdaptHealth sees small but positive trends
May 8, 2024Theresa Flaherty, Managing Editor
PLYMOUTH MEETING, Pa. – AdaptHealth’s diabetes business “outperformed expectations” during the first quarter of 2024 and company execs are cautiously optimistic that their efforts to boost the segment are starting to make headway.
Diabetes revenue was $149.3 million for the quarter, a 2% increase and the first year-over-year increase for the segment since the second quarter of 2023, driven by the company’s moves to double its sales force, name Briah Carey as...
Health care goes OTC
April 26, 2024Theresa Flaherty, Managing Editor
As is par for the course these days, my inbox this month has been filled with diabetes tech announcements: Edgepark is adding a new insulin delivery system to its portfolio, Insulet’s Omnipod is fueling growth and Ascensia is expanding access to its Eversense device by extending its PASS program, which offers a substantial discount for users.
That last one is key: All the technology in the world won’t help if it’s too expensive for people to acquire. And this stuff is expensive...
Ascensia extends PASS program
March 14, 2024HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care and Senseonics Holdings will extend the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversense E3 CGM System more affordably, the program offers major savings for eligible individuals looking to experience the unique benefits of the only long-term CGM system available. Eligible individuals will pay only $99 out of pocket for an unlimited number of six-month Eversense E3 systems under...
CCS ‘on right track’
March 13, 2024Theresa Flaherty, Managing Editor
GLP-1 medications misconception: Nearly 60% of diabetes patients surveyed by CCS mistakenly believe that GLP-1 medications alone are a silver bullet for managing their health. However, these drugs need to be integrated into a long-term holistic care plan.
Education and support gap: The survey results highlight a real need for better education and support for patients managing their diabetes. Diabetes suppliers are well-positioned to...
In brief: AAH on cath fraud & CCS on GLP-1s
March 8, 2024HME News Staff
WASHINGTON – AAHomecare has issued a statement affirming its support for the government to implement real-time monitoring of claims to detect potential fraud and abuse, in response to news reports of potential Medicare fraud by a handful of intermittent catheter companies.
AAHomecare's statement, which was shared with CMS and Capitol Hill, also reiterates recommendations for federal government initiatives to better monitor DME supplier billing practices and trends, including:
Increased...
CCS survey: Education lacking for diabetes
March 7, 2024HME News Staff
DALLAS – CCS engaged independent market research firm PureSpectrum to survey more than 1,500 people living with diabetes to understand their attitude on an array of timely issues, including growing demand for GLP-1 weight loss drugs.
The survey found 57% of people with diabetes think GLP-1 weight loss drugs alone may be a silver bullet for helping achieve their health goals.
“GLP-1 weight loss drugs alone are not a silver bullet when it comes to improving the health...
Dexcom to introduce OTC glucose sensor
March 6, 2024HME News Staff
SAN DIEGO – Dexcom has received clearance from the U.S. Food and Drug Administration for its Stelo by Dexcom, a continuous glucose monitor that will be available for people with Type 2 diabetes without a prescription. “Dexcom continues to lead innovation in the CGM market, with a long list of first-in-market advances,” said Jake Leach, executive vice president and COO. “Dexcom was the first to connect CGM to multiple insulin delivery devices, the first to connect CGM to a...
Know Labs unveils non-invasive CGM
February 29, 2024HME News Staff
SEATTLE – Know Labs, an emerging developer of non-invasive medical diagnostic technology, has unveiled KnowU, a wearable non-invasive continuous glucose monitor (CGM), the result of an accelerated development process over the last eight months. The KnowU incorporates the sensor that the company plans to submit to the U.S. Food and Drug Administration for clearance. “The prevalence of diabetes is growing globally at an alarming rate,” said Ron Erickson, CEO and chairman. “Millions...